Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty


About this study

The purpose of this study is to investigate if bupivacaine +meloxicam ER solution is going to improve patient care at Mayo Clinic through superior and prolonged analgesia following total knee arthroplasty compared to our standard of care.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ASA classification I to III, older than or equal to 18 years old.
  • All genders.
  • Presenting for primary total knee replacement for degenerative joint disease.
  • Patient capable of providing their own informed consent.

Exclusion Criteria:

  • Vulnerable study populations including prisoners.
  • Patients with a contralateral total knee arthroplasty < 2 years prior to the index procedure.
  • Compromised health barring them from proceeding with surgery including acute or chronic kidney injury identified pre-operative.
  • Patients unable to provide their own informed consent.
  • Pregnancy.
  • Patients with documented chronic pain syndromes.
  • Patients with a history of prolonged daily opioids (more than 1 month) with an oral morphine equivalent of greater than 5mg/day.
  • BMI > 45 kg/m^2.
  • Allergies to any component of the study medications, including specific history of type 1 hypersensitivities to any NSAID.
  • Patients with impaired cognitive function.
  • Major systemic illnesses such as severe renal (estimated glomerular filtration rate less than 50ml/min), coronary artery disease requiring a bypass graft (CABG), other cardiac problems including congestive heart failure (CHF New York Heart Association class III to IV), or severe hepatic disorders defined as current or past diagnosis of acute/subacute liver necrosis, acute hepatic failure, chronic liver disease, liver abscess, hepatic coma, hepatorenal syndrome and other disorders of the liver.

Eligibility last updated 10/12/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Abdel, M.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Lauren Cole B.S.

(507) 266-1227

More information


Publications are currently not available

Mayo Clinic Footer